OncoMatch/Clinical Trials/NCT03463252

Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC

Is NCT03463252 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including Progesterone and Mirena® for endometrial cancer.

Phase 2/3RecruitingWest China Second University HospitalNCT03463252Data as of May 2026

Treatment: Progesterone · Mirena® · GnRH agonist — Primary end points: This clinical trial is aimed to analyze the effectiveness of Levonorgestrel-Releasing Intrauterine System (LNG-IUS, Mirena®) in the fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma, including pathology response and pregnancy outcome. Second end points: To analyze the appearances of side-effects.

Check if I qualify

Extracted eligibility criteria

Cancer type

Endometrial Cancer

Biomarker criteria

Required: PR (PGR) positive (positive)

Disease stage

Required: Stage 1A

Grade: 1

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify